Clinical Trial: Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014410) titled 'Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer' on May 05, 2023.

Brief Summary: This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.

Study Start Date: Feb. 01, 2023

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: pyrotinib dalpiciclib letrozole

ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole

Recruitment Status: RECR...